In vivo PET quantification of the dopamine transporter in rat brain with [¹⁸F]LBT-999.
Creators
- 1. Inserm, U930, Tours, France and Université François-Rabelais de Tours, UMR-U930, Tours, France
- 2. Inserm, U930, Tours, France and Université François-Rabelais de Tours, UMR-U930, Tours, France and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire in vitro, Tours, France
- 3. Laboratoires Cyclopharma, Tours, France
Description
INTRODUCTION:
We examined whether [(18)F]LBT-999 ((E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4'-tolyl)nortropane) is an efficient positron emission tomography (PET) tracer for the quantification of the dopamine transporter (DAT) in the healthy rat brain.
METHODS:
PET studies were performed using several experimental designs, i.e. test-retest, co-injection with different doses of unlabelled LBT, displacement with GBR12909 and pre-injection of amphetamine.
RESULTS:
The uptake of [(18)F]LBT-999 confirmed its specific binding to the DAT. The non-displaceable uptake (BP(ND)) in the striatum, between 5.37 and 4.39, was highly reproducible and reliable, and was decreased by 90% by acute injection of GBR12909. In the substantia nigra/ventral tegmental area (SN/VTA), the variability was higher and the reliability was lower. Pre-injection of amphetamine induced decrease of [(18)F]LBT-999 BP(ND) of 50% in the striatum.
CONCLUSIONS:
[(18)F]LBT-999 allows the quantification of the DAT in living rat brain with high reproducibility, sensitivity and specificity. It could be used to quantify the DAT in rodent models, thereby allowing to study neurodegenerative and neuropsychiatric diseases.
Files
Serriere_NuclMedBiol_2014-P04-AAM.pdf
Files
(360.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5c34fdb2a209afd87c6e101836f97015
|
360.6 kB | Preview Download |